New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.

ABSTRACT: The management of heart failure with reduced ejection fraction (HF-REF) has improved significantly over the last two decades. In contrast, little or no progress has been made in identifying evidence-based, effective treatments for heart failure with preserved ejection fraction (HF-PEF). Despite the high prevalence, mortality, and cost of HF-PEF, large phase III international clinical trials investigating interventions to improve outcomes in HF-PEF have yielded disappointing results. Therefore, treatment of HF-PEF remains largely empiric, and almost no acknowledged standards exist. There is no single explanation for the negative results of past HF-PEF trials. Potential contributors include an incomplete understanding of HF-PEF pathophysiology, the heterogeneity of the patient population, in

SUBMITTER: Senni M 

PROVIDER: S-EPMC4204003 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature